Notify me when STEMPOINT CAPITAL LP files a new Schedule 13D/G report.
⭐ Subscribe ⭐| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| XLO | Xilio Therapeutics, Inc. | Common stock, par value $0.0001 per share | 8.4% | $3,979,818 | +$1,339,818 | 6,030,028 | +51% | StemPoint Capital LP | 31 Dec 2025 |
| SRZN | Surrozen, Inc. | Common Stock, $0.0001 par value per share | 7% | $12,798,168 | -$8,186,300 | 619,766 | -39% | StemPoint Capital LP | 31 Dec 2025 |
| VTGN | Vistagen Therapeutics, Inc. | Common Stock, par value $0.001 per share | 1.5% | $456,394 | -$1,266,690 | 616,749 | -74% | StemPoint Capital LP | 31 Dec 2025 |
| Sym | Target | Class | Ownership | Change | Current Shares | Change | Value | Reporting name | Form | Report Period | Filing Date |
|---|